Global Vardenafil Market Research Report 2019 offers a comprehensive evaluation of the drug’s industry, size, share, developments and advancements, applications, key players, key challenges, administrative approaches, etc.
The report mainly focuses on the top leader covering the competitive landscape and gives the drug’s market estimate and forecast until 2025.
The US Food and Drug Administration (FDA) approved Vardenafil for the treatment of erectile dysfunction (ED) in men. It belongs to the class of drugs called PDE5 inhibitors. The drug helps men to achieve and sustain an erection hard and long enough for sexual intercourse.
Other common drugs belonging to the same class of pharmacological agents include sildenafil, tadalafil, and avanafil.
The FDA approved Vardenafil in 2003 after reviewing its clinical trials, safety, and efficacy. It is sold under the brand name Levitra.
The top Vardenafil manufacturers with production, price, and market share include Bayer, GlaxoSmithKline (GSK), Teva, Par Pharmaceutical, Alembic Pharmaceuticals, Macleods Pharmaceuticals, Zydus Pharmaceuticals, and Crossmedika SA.
Vardenafil is available in 2.5 mg, 5 mg, 10 mg, and 20 mg potencies.
The industrial segmentation by product type includes hospitals, local drugstores, and online pharmacies.
The regional analysis of the drug includes North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
According to the Global Vardenafil Market Report 2019, it is estimated that the drug would reach nearly $1 million by the end of 2025 and the market will grow at a CAGR from 2019 to 2025.
One of the key features of the Vardenafil Research Report is to provide a detailed analysis of the market along with a comprehensive understanding of the drug and its commercial landscape.
The report also provides a five-year forecast assessed based on how this ED drug is predicted to grow.
In addition, the report provides insightful analysis of changing competition dynamics. Finally, the Global Vardenafil Market Report 2019 covers the growth aspect in the coming years.
